Quick Answer
Cullinan Therapeutics, Inc. reported Stockholders Equity of $408.73 million for the year ending 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -30.8% in Stockholders Equity from 2024 to 2025.
- This data is from Cullinan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $97.65 million | Q3 2020: $87.65 million | Q1 2021: $466.90 million | Q2 2021: $455.55 million | Q3 2021: $443.39 million | Q1 2022: $418.70 million | Q2 2022: $604.54 million | Q3 2022: $586.13 million | Q1 2023: $485.65 million | Q2 2023: $499.57 million | Q3 2023: $468.82 million | Q1 2024: $425.67 million | Q2 2024: $656.22 million | Q3 2024: $627.86 million | Q1 2025: $551.84 million | Q2 2025: $492.15 million | Q3 2025: $451.37 million.
- Over the full 7 years of available data (2019 to 2025), Cullinan Therapeutics, Inc.'s Stockholders Equity has grown by 321.4%.
- Historical annual values: Fiscal year 2025: $408.73 million | Fiscal year 2024: $590.33 million | Fiscal year 2023: $453.70 million | Fiscal year 2022: $535.03 million | Fiscal year 2021: $424.97 million | Fiscal year 2020: $199.01 million | Fiscal year 2019: $97.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: